San Francisco Bay Area biotech stories.
Tuesday, September 18, 2012
One-on-One with Medivation CEO David Hung
Medivation's David Hung.
The story of Medivation Inc. could belong in the collection of biotech’s greatest comebacks.
The San Francisco company (NASDAQ: MDVN), partner
(NYSE: PFE) and investors pinned many of their hopes on Dimebon, but even before that drug failed, Medivation was working on what now is called Xtandi in prostate cancer. I spoke with Medivation President and CEO
about Xtandi, the competition in the prostate cancer drug arena, Medivation’s pipeline and the likelihood of bringing Dimebon back as an Alzheimer's-fighting drug.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)